(Q59218456)

2

0 references

Brad S Kahl

3

0 references

Stephanie Markovina

4

0 references

Shigeki Miyamoto

describes a project that uses

5

0 references

language of work or name

English

0 references

publication date

19 May 2008

0 references

published in

Molecular Cancer

0 references

volume

7

0 references

issue

1

0 references

page(s)

40

0 references

ImageQuant

object named as

ImageQuant

2 references

Europe PubMed Central

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC2408930/fullTextXML

inferred from PubMed Central ID database lookup

CZ Software Mentions: A large dataset of software mentions in the biomedical literature

exact match

https://scigraph.springernature.com/pub.10.1186/1476-4598-7-40

0 references

cites work

Cancer statistics, 2007

1 reference

12 December 2020

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

1 reference

12 December 2020

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

1 reference

12 December 2020

Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo

1 reference

12 December 2020

Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha

1 reference

12 December 2020

A switch in distinct I kappa B alpha degradation mechanisms mediates constitutive NF-kappa B activation in mature B cells

1 reference

12 December 2020

NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100

1 reference

12 December 2020

Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway

1 reference

12 December 2020

Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha

1 reference

12 December 2020

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

1 reference

12 December 2020

Evidence for unique calmodulin-dependent nuclear factor-kappaB regulation in WEHI-231 B cells

1 reference

12 December 2020

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

1 reference

12 December 2020

Missing pieces in the NF-kappaB puzzle

1 reference

12 December 2020

NF-kappaB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression

1 reference

12 December 2020

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

12 December 2020

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

12 December 2020

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

1 reference

12 December 2020

Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.

1 reference

12 December 2020

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

1 reference

12 December 2020

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

12 December 2020

CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response

1 reference

12 December 2020

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

1 reference

12 December 2020

Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects

1 reference

12 December 2020

A mechanistic insight into a proteasome-independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells

1 reference

12 December 2020

Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells.

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

12 December 2020

Approval summary for bortezomib for injection in the treatment of multiple myeloma

1 reference

12 December 2020

Signaling to NF-kappaB

1 reference

12 December 2020

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

12 December 2020

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

1 reference

12 December 2020

Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors

1 reference

12 December 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

12 December 2020

Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites.

1 reference

12 December 2020

Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation

1 reference

12 December 2020

Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene

1 reference

12 December 2020

A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study

1 reference

12 December 2020

Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol

1 reference

12 December 2020

Transforming growth factor beta and cell cycle regulation

1 reference

12 December 2020

LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha

1 reference

12 December 2020

Inhibitors of mammalian G1 cyclin-dependent kinases

1 reference

12 December 2020

Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol

1 reference

12 December 2020

Supravital exposure to propidium iodide identifies apoptotic cells in the absence of nucleosomal DNA fragmentation

1 reference

12 December 2020

Mantle cell lymphoma: a clinicopathologic study of 80 cases

1 reference

12 December 2020

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

Cancer chemoprevention and therapy by monoterpenes

1 reference

12 December 2020

Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer

1 reference

12 December 2020

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells

1 reference

12 December 2020

Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells

1 reference

12 December 2020

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

1 reference

12 December 2020

Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells.

1 reference

12 December 2020

Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation

1 reference

12 December 2020

The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells

1 reference

12 December 2020

Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells

1 reference

12 December 2020

Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IκBα/NF-κB pathway in limb-girdle muscular dystrophy type 2A

1 reference

12 December 2020

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

12 December 2020

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

12 December 2020

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

12 December 2020

Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IkappaBalpha degradation in B cells

1 reference

12 December 2020

Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma

1 reference

12 December 2020

Biology and therapy of mantle cell lymphoma

1 reference

12 December 2020

Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway

1 reference

12 December 2020

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

12 December 2020

IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy

1 reference

12 December 2020

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

1 reference

12 December 2020

Bortezomib: proteasome inhibition as an effective anticancer therapy

1 reference

12 December 2020

Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives

1 reference

12 December 2020

NF-kappaB and IKK as therapeutic targets in cancer

1 reference

12 December 2020

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

1 reference

12 December 2020

Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas

1 reference

12 December 2020

Nuclear factor-kappaB in cancer development and progression

1 reference

12 December 2020

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

1 reference

12 December 2020

Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network

1 reference

12 December 2020

Detection and localization of calpain 3-like protease in a neuronal cell line: possible regulation of apoptotic cell death through degradation of nuclear IkappaBalpha

1 reference

12 December 2020

Deregulated NF-kappaB activity in haematological malignancies

1 reference

12 December 2020

Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa

1 reference

12 December 2020

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

1 reference

12 December 2020

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

12 December 2020

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

1 reference

12 December 2020